HENGRUI PHARMA (01276.HK): Hetrombopag Olamine Tablets approved for two additional indications, becoming world's first TPO-RA approved for CTIT

NewTimeSpace News: On 10 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) announced that it has recently received notice from the National Medical Products Administration approving two additional indications for Hetrombopag Olamine Tablets, a Class 1 innovative drug independently developed by the company.

According to the announcement, the new indications are for adult patients with chemotherapy-induced thrombocytopenia (CTIT) caused by anti-tumour therapy primarily comprising solid tumour chemotherapy, and for paediatric patients aged 6 and above with chronic primary immune thrombocytopenia (ITP) who have had an inadequate response to treatments such as corticosteroids and immunoglobulins, to increase platelet counts and reduce or prevent bleeding, and only for ITP patients whose thrombocytopenia and clinical conditions increase the risk of bleeding. The drug is in tablet form with strengths of 2.5mg and 2.5mg, 3.75mg and 5mg, classified as a Category 2.4 chemical drug and available by prescription.

The announcement stated that Hetrombopag Olamine Tablets had previously been approved for three indications: chronic primary ITP in adults with inadequate response to corticosteroids and immunoglobulins, severe aplastic anaemia (SAA) in adults with inadequate response to immunosuppressive therapy (IST), and in combination with IST for previously untreated SAA patients aged 15 and above. Hetrombopag is China's first independently developed non-peptide oral TPO-RA, and the new approval makes it the world's first thrombopoietin receptor agonist (TPO-RA) approved for CTIT. Comparable products, including Eltrombopag (brand name Promacta), Avatrombopag (brand name Doptelet) and Lusutrombopag (brand name Mulpleta), are all approved in China, with combined global sales of approximately USD 2.222 billion in 2025 according to EvaluatePharma. Cumulative R&D investment in the project amounts to approximately RMB 657.70 million (unaudited). 

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.